Product Code: GVR-3-68038-154-2
Heparin Market Growth & Trends:
The global heparin market size is expected to reach USD 9.03 billion by 2030, expanding at a CAGR of 2.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing geriatric population and heightened demand for transfusions are key factors propelling the market growth. Moreover, the outbreak of COVID-19 has further propelled the market growth. For instance, as per The Lancet Journal in 2022, the demand for heparin exacerbated attributable to its use in COVID-19 patients for thromboprophylaxis.
Increasing demand for blood components, transfusion, and plasma derivatives in the treatment of infectious diseases is expected to drive the market. For instance, according to American Red Cross in 2022, around 16 million blood components are transfused each year in the U.S. Furthermore, the surge in the number of surgeries that were delayed due to the COVID-19 pandemic has further escalated the demand for heparin for blood-clot prevention.
The growing geriatric population is estimated to fuel the market growth. According to United Nations, it was estimated that, in 2020, there were around 727 million people with ages above 60 years worldwide. In addition, the percentage share of the aged population above 65 years is estimated to increase from 9.3% in 2020 to 16% in 2050. The geriatric population has a higher rate of complex surgeries and thus is anticipated to propel the demand for heparin as an anticoagulant, as this population has a significantly higher rate of developing blood clots and related conditions such as deep vein thrombosis.
The growing number of surgeries is a key factor accelerating the demand for whole blood and transfusions. For instance, the annual number of major surgeries performed globally has reached 310 million, 40 to 50 million surgeries performed in the U.S., and around 20 million were performed in Europe in 2020. These surgeries are projected to escalate the demand for heparin.
The competitive rivalry in the marketplace is expected to be moderate due to changing dynamics towards oral anticoagulants. The involvement of players in discovering novel routes of administration for anticoagulants such as heparin is expected to change the market scenario over the forecast period. The rising number of players offering generics also increases competitive rivalry.
Heparin Market Report Highlights:
- The Low Molecular Weight Heparin (LMWH) segment held the largest revenue share in 2023 owing to its high prescription rate and demand
- The subcutaneous route of administration segment held the largest revenue share in 2023 owing to its cost-effective nature and easier procedure for administration
- The coronary artery disease segment dominated the market in 2022 owing to the rising incidence of coronary artery disease and increased use of heparin injection in hospitalized patients
- The outpatient segment is expected to hold the largest revenue share in 2023 owing to the initiatives undertaken by hospitals for outpatient services and the increased preference of patients for outpatient treatment
- Porcine-derived heparin is expected to dominate the market due to its use in the production of low molecular weight heparin
- Asia Pacific is expected to exhibit the fastest growth over the forecast period due to the growing establishment of healthcare, and a large population base
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Route of administration
- 1.2.3. Application
- 1.2.4. End-use
- 1.2.5. Source
- 1.2.6. Regional scope
- 1.2.7. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type
- 2.2.2. Route of Administration
- 2.2.3. Application
- 2.2.4. End-use
- 2.2.5. Source
- 2.2.6. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Heparin Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing prevalence of chronic diseases
- 3.2.1.2. Growing demand for whole blood and blood components transfusion
- 3.2.1.3. Increasing geriatric population
- 3.2.1.4. High usage of plasma in the pharmaceutical industry
- 3.2.2. Market restraint analysis
- 3.2.2.1. Risk of blood-transmitted diseases and an increasing number of blood substitutes
- 3.2.2.2. Emerging oral anticoagulants
- 3.3. Heparin Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
Chapter 4. Heparin Market: Type Estimates & Trend Analysis
- 4.1. Type Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Heparin Market by Type Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Low Molecular Weight Heparin
- 4.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.2. Ultra-low Molecular Weight Heparin
- 4.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3. Unfractionated Heparin
- 4.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Heparin Market: Route of Administration Estimates & Trend Analysis
- 5.1. Route of Administration Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Heparin Market by Route of Administration Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Intravenous
- 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.2. Subcutaneous
- 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. Heparin Market: Application Estimates & Trend Analysis
- 6.1. Application Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Heparin Market by Application Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. Venous Thromboembolism
- 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.2. Atrial Fibrillation
- 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.3. Renal Impairment
- 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.4. Coronary Artery Disease
- 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.5. Others
- 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Heparin Market: End-use Estimates & Trend Analysis
- 7.1. End-use Market Share, 2023 & 2030
- 7.2. Segment Dashboard
- 7.3. Global Heparin Market by End-use Outlook
- 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.4.1. Outpatient
- 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Inpatient
- 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. Heparin Market: Source Estimates & Trend Analysis
- 8.1. Source Market Share, 2023 & 2030
- 8.2. Segment Dashboard
- 8.3. Global Heparin Market by Source Outlook
- 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 8.4.1. Porcine
- 8.4.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.4.2. Bovine
- 8.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Others
- 8.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 9. Heparin Market: Regional Estimates & Trend Analysis
- 9.1. Regional Market Share Analysis, 2023 & 2030
- 9.2. Regional Market Dashboard
- 9.3. Global Regional Market Snapshot
- 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
- 9.5. North America
- 9.5.1. U.S.
- 9.5.1.1. Key country dynamics
- 9.5.1.2. Regulatory framework/ reimbursement structure
- 9.5.1.3. Competitive scenario
- 9.5.1.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.5.2. Canada
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework/ reimbursement structure
- 9.5.2.3. Competitive scenario
- 9.5.2.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6. Europe
- 9.6.1. UK
- 9.6.1.1. Key country dynamics
- 9.6.1.2. Regulatory framework/ reimbursement structure
- 9.6.1.3. Competitive scenario
- 9.6.1.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.2. Germany
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework/ reimbursement structure
- 9.6.2.3. Competitive scenario
- 9.6.2.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.3. France
- 9.6.3.1. Key country dynamics
- 9.6.3.2. Regulatory framework/ reimbursement structure
- 9.6.3.3. Competitive scenario
- 9.6.3.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.4. Italy
- 9.6.4.1. Key country dynamics
- 9.6.4.2. Regulatory framework/ reimbursement structure
- 9.6.4.3. Competitive scenario
- 9.6.4.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.5. Spain
- 9.6.5.1. Key country dynamics
- 9.6.5.2. Regulatory framework/ reimbursement structure
- 9.6.5.3. Competitive scenario
- 9.6.5.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.6. Norway
- 9.6.6.1. Key country dynamics
- 9.6.6.2. Regulatory framework/ reimbursement structure
- 9.6.6.3. Competitive scenario
- 9.6.6.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.7. Sweden
- 9.6.7.1. Key country dynamics
- 9.6.7.2. Regulatory framework/ reimbursement structure
- 9.6.7.3. Competitive scenario
- 9.6.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.8. Denmark
- 9.6.8.1. Key country dynamics
- 9.6.8.2. Regulatory framework/ reimbursement structure
- 9.6.8.3. Competitive scenario
- 9.6.8.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.7. Asia Pacific
- 9.7.1. Japan
- 9.7.1.1. Key country dynamics
- 9.7.1.2. Regulatory framework/ reimbursement structure
- 9.7.1.3. Competitive scenario
- 9.7.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.7.2. China
- 9.7.2.1. Key country dynamics
- 9.7.2.2. Regulatory framework/ reimbursement structure
- 9.7.2.3. Competitive scenario
- 9.7.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.7.3. India
- 9.7.3.1. Key country dynamics
- 9.7.3.2. Regulatory framework/ reimbursement structure
- 9.7.3.3. Competitive scenario
- 9.7.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.7.4. Australia
- 9.7.4.1. Key country dynamics
- 9.7.4.2. Regulatory framework/ reimbursement structure
- 9.7.4.3. Competitive scenario
- 9.7.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.7.5. South Korea
- 9.7.5.1. Key country dynamics
- 9.7.5.2. Regulatory framework/ reimbursement structure
- 9.7.5.3. Competitive scenario
- 9.7.5.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.7.6. Thailand
- 9.7.6.1. Key country dynamics
- 9.7.6.2. Regulatory framework/ reimbursement structure
- 9.7.6.3. Competitive scenario
- 9.7.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.8. Latin America
- 9.8.1. Brazil
- 9.8.1.1. Key country dynamics
- 9.8.1.2. Regulatory framework/ reimbursement structure
- 9.8.1.3. Competitive scenario
- 9.8.1.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.8.2. Mexico
- 9.8.2.1. Key country dynamics
- 9.8.2.2. Regulatory framework/ reimbursement structure
- 9.8.2.3. Competitive scenario
- 9.8.2.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.8.3. Argentina
- 9.8.3.1. Key country dynamics
- 9.8.3.2. Regulatory framework/ reimbursement structure
- 9.8.3.3. Competitive scenario
- 9.8.3.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.9. MEA
- 9.9.1. South Africa
- 9.9.1.1. Key country dynamics
- 9.9.1.2. Regulatory framework/ reimbursement structure
- 9.9.1.3. Competitive scenario
- 9.9.1.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.9.2. Saudi Arabia
- 9.9.2.1. Key country dynamics
- 9.9.2.2. Regulatory framework/ reimbursement structure
- 9.9.2.3. Competitive scenario
- 9.9.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.9.3. UAE
- 9.9.3.1. Key country dynamics
- 9.9.3.2. Regulatory framework/ reimbursement structure
- 9.9.3.3. Competitive scenario
- 9.9.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.9.4. Kuwait
- 9.9.4.1. Key country dynamics
- 9.9.4.2. Regulatory framework/ reimbursement structure
- 9.9.4.3. Competitive scenario
- 9.9.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Recent Developments & Impact Analysis, By Key Market Participants
- 10.2. Company/Competition Categorization
- 10.3. Vendor Landscape
- 10.3.1. List of key distributors and channel partners
- 10.3.2. Key customers
- 10.3.3. Key company market share analysis, 2023
- 10.3.4. Pfizer Inc.
- 10.3.4.1. Company overview
- 10.3.4.2. Financial performance
- 10.3.4.3. Type benchmarking
- 10.3.4.4. Strategic initiatives
- 10.3.5. LEO Pharma A/S
- 10.3.5.1. Company overview
- 10.3.5.2. Financial performance
- 10.3.5.3. Type benchmarking
- 10.3.5.4. Strategic initiatives
- 10.3.6. Dr. Reddy's Laboratories Ltd.
- 10.3.6.1. Company overview
- 10.3.6.2. Financial performance
- 10.3.6.3. Type benchmarking
- 10.3.6.4. Strategic initiatives
- 10.3.7. GlaxoSmithKline plc
- 10.3.7.1. Company overview
- 10.3.7.2. Financial performance
- 10.3.7.3. Type benchmarking
- 10.3.7.4. Strategic initiatives
- 10.3.8. Sanofi
- 10.3.8.1. Company overview
- 10.3.8.2. Financial performance
- 10.3.8.3. Type benchmarking
- 10.3.8.4. Strategic initiatives
- 10.3.9. Aspen Holdings
- 10.3.9.1. Company overview
- 10.3.9.2. Financial performance
- 10.3.9.3. Type benchmarking
- 10.3.9.4. Strategic initiatives
- 10.3.10. Fresenius SE & Co. KGaA
- 10.3.10.1. Company overview
- 10.3.10.2. Financial performance
- 10.3.10.3. Type benchmarking
- 10.3.10.4. Strategic initiatives
- 10.3.11. B. Braun Medical, Inc.
- 10.3.11.1. Company overview
- 10.3.11.2. Financial performance
- 10.3.11.3. Type benchmarking
- 10.3.11.4. Strategic initiatives
- 10.3.12. Sandoz (Novartis AG)
- 10.3.12.1. Company overview
- 10.3.12.2. Financial performance
- 10.3.12.3. Type benchmarking
- 10.3.12.4. Strategic initiatives